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Cleavage of the third component of complement (C3) and subsequent assembly of 
the attack mechanism  (C5-C9)  occurs as a  function of at least two distinct  enzymes 
generated during the activation of the classical (1) and the alternative (2-4) pathways. 
The classical pathway C3 convertase is formed in the fluid phase (5), or is bound to 
particles (6) by a sequential reaction involving the reversible binding of C2 to C4b in 
the presence of Mg  2 to form the C4b2 complex, and by subsequent cleavage of the 
bound  C2  by CTs to generate C4b2a  (7).  The latter decays by dissociation of C2a, 
becoming functionally inactive C2i (8). C4b and CTs remain in their active state and 
are  able  to  regenerate  the  convertase with  additional  C2  (8).  These  reactions  are 
remarkably similar to those occurring during the formation of the alternative pathway 
C3 convertase (3, 4). 
Although  a  great deal of knowledge has been accumulated on the modulation  of 
the alternative pathway (9, 10), the same information relating to the classical pathway 
enzyme is less complete, except for the knowledge that the C4b2a, formed either on 
particles or in the fluid phase, is thermolabile (5, 6). At physiologic temperatures, the 
C2a fragment is released from the complex with a  half-life of 7 min, thus rendering 
the enzyme inactive. The recent  demonstration of a  serum protein, designated C4b 
binding protein  (C4-bp), 1 which  exhibits  a  marked affinity for C4b  (11),  suggested 
that  this protein  may also regulate the  function  of the C4b2a enzyme.  It has been 
shown that C4-bp accelerates the decay rate of C4b2a (12)  by dissociating C2a from 
C4b  (13).  Therefore,  similarly  to fllH  in  the  alternative  pathway  (14,  15),  C4-bp 
provides  the  means  for an  extrinsic  decay of C4b2a.  C4-bp  may also regulate  the 
generation of C4b2a enzyme by impairing the uptake of C2 by C4b (12). The capacity 
of C4b to form the classical pathway C3 convertase is limited by the proteolytic action 
of the serum enzyme C4b/C3b  inactivator  (C4b/C3bINA).  This reaction  results in 
the cleavage of the a' polypeptide chain of C4b yielding the C4d (a2) fragment of the 
a' chain, and C4c, which contains the two remaining fragments of the a' chain  (a3 
and c~4) and the intact fl and y  chains  (12).  Cleavage of C4b in the fluid phase by 
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C4b/C3bINA  absolutely requires the presence of C4-bp (16,  17), whereas the surface- 
bound C4b proceeds independently of these proteins (12). 
In contrast to these reactions, which dampen the formation and function of C4b2a, 
a  plasma  protein  that  is  functionally characterized  by  its  capacity  to  stabilize the 
classical pathway C3 convertase has recently been described (18,  19). This protein, a 
gammaglobulin,  has  been  isolated  from  the  plasma  of one  patient  suffering  from 
acute  post-infectious glomerulonephritis  (18)  and  from  some patients with  systemic 
lupus  erythematosus  (SLE)  (19).  Because  of  the  physicochemical  and  functional 
similarities with  C3  nephritic  factor  (C3Nef;  20),  it  has  been  postulated  that  this 
protein  may  represent  an  antibody  to  the  C4b2a  enzyme.  It  has  been  termed  the 
nephritic factor of the classical pathway (NFc;  18). 
In this paper, we describe the mechanism  of action of NFc and its relationship to 
the control proteins C4-bp and C4b/C3bINA.  We demonstrate that  it prevents the 
intrinsic decay of C4b2a, as well as the extrinsic decay mediated by the effect of C4- 
bp. In addition, we show that the C4b in the stable C4b2a enzyme is protected from 
the proteolytic action of the C4b/C3bINA. 
Materials  and  Methods 
Reagents.  Agarose was obtained from Behring Diagnostics, American Hoechst Corp., Som- 
merville, N. J.;  N,N'-methylene-bisac~'ylamide, N,N,N',N'-tetramethylethylenediamine,  am- 
monium persulphate, and sodium dodecyl sulphate were obtained from Bio-Rad, Richmond, 
Calif.; diisopropylfluorophosphate was purchased from Calbiochem; San Diego, Calif. 
Buffers.  Phosphate-buffered  saline  (Dulbecco's  PBS)  was  obtained  from  Grand  Island 
Biological Co.,  Grand  Island,  N.  Y.  Other  buffers used  were  PBS  containing 2  mM  NaaH 
EDTA,  pH  7.55;  barbital buffer,  pH  8.6,  containing 0.023  M  sodium  barbital, 0.0037  M 
barbituric acid; 0.002  M  barbital, with  NaC1 added to achieve a  conductivity of 7.4 mS at 
0°C, and 0.002 M NaaH EDTA (VBS-EDTA); veronal-buffered saline containing 0.1% gelatin, 
0.005  M  MgC12, and 0.00015 M  CaCI~;  GVB  = mixed with an equal volume of 5% dextrose in 
water containing 0.005 M  MgCI2 and 0.00015 M  CaCI2 (DGVB++). 
Purified Complement Components.  Guinea pig and human C1  (21)  and CT~,; (22),  human  C4 
(23),  C2  (24),  C4-bp  (11),  C3~ C5  (25),  and  C4b/C3bINA  (26)  were  purified by published 
techniques. C4 was radiolabeled with 125I as described (27);  the specific activity was 24 ×  10  ~ 
cpm/~g of protein. These proteins were quantitated functionally by hemolytic techniques and 
their protein concentration  was  measured  by the  method  of Lowry et  al.  (28),  or by their 
absorbance at 280 nm, assuming that an absorption of 1.0 equals 1 mg of protein/ml. 
Cellular Intermediates and Assays.  EA  and  EAC1  were  prepared  from  sheep  erythrocytes, 
rabbit anti-sheep erythrocytes, and human CT, and were converted to EACT4b by using highly 
purified C4  at  a  concentration of 6/~g/1  X  108 cells (12).  The C4  deposited on the cellular 
intermediate EACT4b represented 10% of the C4 input, as assessed by an uptake of 125I-labeled 
C4.  C4, C2, and C3 were measured by hemolytic titrations (29).  Rat serum diluted  1:20  in 
EDTA-GVB  = was used as a  source of C3-C9.  The C6,  C7, C8,  and C9  used in C3  and C5 
titrations were purchased from Cordis Laboratories (Miami, Fla.). 
Isolation and Purification of the NFc.  The identification of this factor was originally reported 
on serum and EDTA plasma from a  patient (R. A. M.) with postinfectious acute glomerulo- 
nephritis  (18).  The  purification, as previously described  (18),  consisted of separation of the 
euglobulin fraction of the plasma, or serum, obtained by dialysis against 5 mM PO4,  pH 5.9, 
containing  2.5  mM  EDTA.  The  supernate  was  then  applied to  a  carboxymethyl cellulose 
column equilibrated with the same buffer and eluted with a salt gradient. The samples with 
NFc activity eluted between  7 and  14 ms. They were pooled, concentrated, and applied to a 
Sephadex G-200 column  in  PBS.  The stabilizing activity was  found superimposed with the 
ascending portion of the IgG peak;  its physicochemical characteristics have been previously 
described (18). 
Structural Analysis of Cell-Bound 125I-labeled C4.  Sodium dodecyl sulphate-polyacrylamide gel GIGLI, SORVILLO,  MECARELLI-HALBWACHS, AND  LEIBOWITCH 
electrophoresis (SDS-PAGE)  was  performed as previously described (30).  In all cases, a  3% 
stacking gel  and  5-15%  gradient  running  gels  were  used.  Approximate molecular weight 
determinations under reducing conditions were calculated by using the purified C4 as standard. 
Cellular intermediates, carrying 12~I-labeled C4,  were lysed in  50  mM  Tris-HCl, pH 6.8, 
containing 2% NaDodSO4, 6 M  urea, 10% glycerol, and 0,1 M dithiothreitol. The samples were 
heated for 3 min in boiling water and applied to polyacrylamide gels. After electrophoresis, the 
gels were stained and dried. Radioautography was carried out by exposing the dried gels to an 
X-omat  R  film XR-S at  -70°C  for  12-72  h.  Supernatant  fluids were analyzed in the same 
manner after the proteins were precipitated using trichloroacetic acid. 
Results 
EA CT4b2a: Formation and Functional Stabilization in the Presence of  NFc.  To demonstrate 
the effect of NFc on the formation of the classical pathway convertase, four samples 
of EAC~4b  cells, prewarmed  at  30°C,  were  incubated  with  an  equal  volume  of a 
limited concentration of C2 diluted with DGVB ++, or with increasing concentrations 
0'f NFc.  Samples  were  removed  at  zero  time,  and  at  intervals  thereafter,  and  the 
C4b2a activity generated was developed with rat complement in EDTA. As shown in 
Fig.  1, the presence of NFc during the generation of C4b2a resulted in the detection 
of more C3 convertase sites. This was evidenced by increased lysis of the EAC4b2a by 
the  rat  complement  in  EDTA  that  was  used  as  a  source  of C3  to  C9.  Once  the 
maximal  reactivity  of the  cells  was  reached,  the  hemolytic  potential  of  the  cells 
remained  unchanged  throughout  the  60  min  of incubation,  as compared  with  the 
EAC~4b2a  generated  either  in  the  presence  of  low  concentrations  of  NFc  or  in 
DGVB ++. Thus, it appears that NFc augments C3 deposition and the assembly of the 
attack mechanism, resulting in increased lysis. 
That EAC]'4b2a, prepared in the presence of NFc, augmented C3 cleavage and the 
initiation of the assembly of the membrane  attack mechanism,  was  investigated by 
measuring the amount of C2, C3, and C5 consumed by these EACT4b2a  prepared in 
the  presence  of NFc.  Two  samples  of EACT4b2a  were  generated  with  excess  C2, 
diluted  either  in  buffer  or  in  buffer  containing  NFc.  The  cells were  separated  by 
centrifugation and  the supernate was kept  for measurement  of residual C2  activity. 
The  cells were  then  washed  with  ice cold buffer,  resuspended  in  buffer containing 
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F]c.  I.  Formation of cell-bound C4b2a. Four samples ofEACT4b  (l X l0  s ml) were prewarmed 
at 30°C and incubated with an equal  volume of C2 (0.5 functionally effective molecules 1 x  l0  s 
cells) diluted in DGVB ++ (0), or 20/.tg/ml NFc (/k); l0/Lg/ml (l); 5 #g/ml (O). At zero time and 
intervals thereafter,  0,5 ml was removed and added to 0.75 ml of rat complement diluted 1:20 in 
0.04 M EDTA in GVB ~. After 1 h at 37°C, 2.5 ml of saline was added, the unlysed erythrocytes 
were sedimented by centrifugation,  and the hemoglobin in the supernate was read in a spectropho- 
tometer at OD414. The percent  lysis as compared with a sample of cells 100% lysed was calculated 
and expressed as Z = -In  ~  . 
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excess C3, and further incubated at 37°C for  1 h. The cells were separated and the 
supernate were measured for residual C3 hemolytic activity and compared with a C3 
sample that was incubated in buffer alone. A sample of EAC~4b3b cells, prepared in 
the absence of NFc after prolonged incubation to assure complete decay of C2, was 
divided into four equal aliquots that received either C2, C2 and NFe, NFc alone, or 
buffer. After 15 rain incubation at 30°C, the cells were washed and their capacity to 
use  C5  was  measured  by  incubating each  cell  preparation with  purified C5.  The 
results of these experiments are shown in Fig. 2. EAC~4b  incubated with C2 in the 
presence of NFc consumed less C2. However, the convertase generated was capable of 
consuming more C3 (44%), as compared with the C3 convertase formed in the absence 
of NFc (14%). A  greater use of C5 by the C5 convertase prepared in the presence of 
NFc was  also shown  (48  and  18%,  respectively). It  should be emphasized that  this 
increase in C5 use was not due to a larger number of C3b present on the erythrocytes 
because the C3b was originally deposited using EAC~4b2a  prepared in the absence 
of NFc. These experiments demonstrate that the enhanced hemolytic activity observed 
in the presence of NFc was not due to the generation of a  larger number of C4b2a. It 
is significant that the results also show that in addition to the C4b2a convertase, NFc 
affects the function of the C5 convertase (C4b2a3b). 
Next,  we  investigated  the  effect  of  NFc  on  the  decay  of  cell-bound  C4b2a. 
EAC~4b2a cells were  prepared  with  a  limited concentration of C2.  The cells were 
washed  in  DGVB  ++  and  divided  into  four  equal  samples.  These  samples  were 
prewarmed  at  30°C  and  at  zero  time  each  was  mixed  with  an  equal  volume of 
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Fla.  2.  C2, C3, and C5 use by EACT4b and C2 in buffer or in buffer with 40/tg of IgG containing 
NFc activity. EAC~4b2a were prepared with excess C2 diluted in buffer or in buffer containing 40 
/~g NFc. After 15 rain incubation at 30°C, the supernate was separated and measured for residual 
C2 activity. The cells were washed and resuspended in buffer containing C3. A sample of EAC]'4b 
preineubated with NFc without C2 was included as control. After 60 min incubation at 37°C, the 
supernatant  fluid was  measured for  residual C3  activity. The EACT4b3b were generated by 
incubated EACT4b2a with C3 in the absence of NFc, followed by decay of C2. These cells were 
converted to EAC]'4b2aC3b or EAC]'4b2a3b (NFc) by incubation with C2 in buffer or C2 in buffer 
containing NFc. After 15 min of incubation at 30°C, the cells were washed in ice cold buffer and 
mixed with buffer containing purified C5. The mixtures were incubated 60 rnin at 37°C and the 
residual C5 was measured in the supernatant fluids. GIGLI,  SORVILLO,  MECARELLI-HALBWACHS,  AND  LEIBOWITCH 
prewarmed DGVB  ++ containing increased amounts of NFc or DGVB  ++ alone. 0.5-ml 
samples were removed at intervals and the C4b2a sites/cells were assessed by adding 
rat  complement-EDTA.  The  results  (Fig.  3)  demonstrate  that  C3  convertase  on 
EACT4b2a incubated with buffer decayed with a  half-life of 7.5  min, whereas in the 
presence of increasing concentrations  of NFc,  the  decay was abolished.  The initial 
decay observed at low NFc concentration may represent unstabilized C4b2a sites. In 
a  separate experiment,  it  was shown  that  IgG or IgM isolated  from normal serum 
failed  to  alter  the  decay  of the  C3  convertase,  and  that  the  stabilized  convertase 
remained fully active after 5 h of incubation at 30°C. 
Protection of  EA C74b2a (NFc)  from Accelerated  Decay by C4-bp.  The capacity of C4-bp 
to accelerate the intrinsic decay of the stabilized C3 convertase (C4b2a) was investi- 
gated in the following experiment. EAC~4b2a  and EACT4b2a  (NFc) were generated 
by incubating equal samples of EACT4b with C2, diluted in DGVB  ++ or in DGVB  ++ 
containing  NFc.  Each  sample  was  washed  in  ice  cold  DGVB  +÷,  resuspended  in 
DGVB  ++, and divided into two equal aliquots. One sample of each received 9.5 ml of 
DGVB  ++ and the other received 9.5 ml of DGVB  ++ containing C4-bp. At the time of 
mixing, and at intervals thereafter, 0.5-ml samples were removed from each mixture 
and the number of remaining C4b2a sites was measured hemolytically. The half-life 
of the C4b2a enzyme (Fig. 4) when incubated in buffer alone was 7.5 min, but it was 
shortened to 2.5 min in the presence of C4-bp. In contrast, C4-bp failed to alter the 
hemolytic activity of the stabilized convertase. A dose response of the effect of C4-bp 
demonstrated that  the stabilized enzyme was totally resistant  to the effect of C4-bp 
even  at  doses  30  times  greater  than  that  sufficient  to  accelerate  the  decay of the 
nonstabilized convertase by >50%. 
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Flo.  3.  Decay of EAC14b2a and EAC]'4b2a  (NFc). EAC]'4b2a were prepared by incubating for 
5 min. EAC]'4b (1 X  l0  s cells/ml) were prewarmed at 30°C with C2 diluted in DGVB  ++ to contain 
5 functionally effective U/1  X  10  s cells.  The cells  were washed in cold DGVB  ++ and resuspended 
in the same buffer to a  concentration of 5  X  108/ml.  1-ml samples were added:  one to DGVB  ++ 
(O), and one each to IgG containing NFc activity diluted in DGVB  ++ to final concentrations of 40 
#g (A), 20 #g ('),  and 5 #g (©). The final cell concentration was 5 x  107/ml.  At the time of mixing 
and at intervals thereafter, 0.5  ml was removed from each reaction mixture and added  to 0.75  ml 
of rat complement diluted in 0.04  M  EDTA-GVB', and the hemoglobin released was measured as 
described after 1 h incubation at 37°C. MECHANISM  OF  ACTION  OF  THE  C4  NEPHRITIC  FACTOR 
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FIc.  4.  Effect  of C4-bp  on  the  decay  of EAC14b2a  and EACT4b2a  (NFc).  EAC14b2a  and 
EAC~4b2a (NFc) were generated by incubating for 5 rain at 30°C two  15-ml samples of  EACl'4b 
(1 ×  10a/ml) with an equal volume of C2 containing 5 effective U/l  ×  10  s cells diluted in DGVB  ++ 
alone, or  in  DGVB  ++  containing 20 ~tg NFc.  The cells were washed and  resuspended in  1.5  ml 
DGVB  ÷+, and two 0.5-ml aliquots were removed from each sample. One aliquot of each received 
9.5 ml DGVB++: EAC]'4b2a (O)  and EAC14b2a (NFc)  (&), and the other two received 9.5 ml C4- 
bp  (10/.tg/1  ×  l0  s cells), EAC14b2a  (O), EACT4b2a (NFc)  (A), both prewarmed at 30°C. At the 
time of mixing and at intervals thereafter, 0.5-ml samples were removed from each reaction mixture 
and the number of C4b2a sites were developed by the addition of 0.75 ml of rat complement-EDTA. 
After 60 min incubation at 37°C, the amount of hemoglobin released by each sample was measured. 
The  ordinate  depicts  the  hemolytic  activity  of each  sample  during  the  decay  time,  which  is 
represented by the abcissa. 
TABLE  I 
Release of Radioactivity  from EACT4b2a and EAC[4b2a (NFc) by the Regulatory Proteins C4-bp and 
C4b/C3blNA 
EACT4b2a (NFc)  EACI4b2a 
C4-bp  C4-bp  C4b/  C4b/ 
C4b/  C4-bp  C3bINA  Buffer  C4b/  C4-bp  C3bINA  Buffer 
C3bINA  C3bINA 
Percent counts released  9  3  6  1  53  7  42  6 
Percent counts on cells  89  96  91  95  43  93  56  92 
Cells were prepared with ~2~I-C4. Total counts in each reaction mixture, 17,500 +  2'~_ 
Protection of C4b in EAC74b2a  (NFc) from  Proteolytic Cleavage by C4b/C3bINA.  The 
susceptibility of C4b2a  (NFc) to  the  proteolytic action  of the  C4b/C3bINA  was 
investigated  structurally  and  functionally.  Two samples  of EAC14b  cells,  prepared 
with 12SI-labeled  C4, were incubated with excess C2 and either buffer or NFc.  After 
30  rain  of  incubation  at  30°C,  the  cells  were  centrifuged,  washed  with  ice  cold 
DGVB ++,  and  resuspended  in  the  same buffer.  Each  sample  was  divided  into  four 
aliquots and incubated with either DGVB ++, C4-bp, C4b/C3bINA, or with both C4- 
bp  and C4b/C3bINA.  After  1 h  at  37°C,  DGVB ++ was added  to each sample,  the 
supernatant  fluids  were  removed  and  the  cells  were  carefully  washed  with  cold 
DGVB ++.  Subsequently,  the radioactivity of the cells and supernates was measured 
(Table  I).  The cells  were  then  lysed,  the  membranes  were  solubilized  in  SDS-urea, 
and both the membranes and the supernates were subjected  to SDS-PAGE,  and an GIGLI, SORVILLO,  MECARELLI-HALBWACHS, AND  LEIBOWITCH 
FIo. 5.  Cleavage  of C4b  in EAC]'4b2a  and EACT4b2a (NFc) by C4-bp  and  C4b/C3bINA. 
EAC]'4b  prepared with  129I-C4 were converted  to EAC]'4b2a  with  C2  diluted either in  buffer 
containing NFc or alone. The EAC]'4b2a  (NFc) and EAC]'4b2a generated were each divided into 
four equal samples; one sample of each  received either C4-bp  and C4b/C3bINA, C4-bp,  C4b/ 
C3bINA, or GVB  ÷+. After 1 h at 37°C, the cells were separated, washed until the supernates were 
free of radioactivity. The cells were lysed and the membranes were dissolved in dithiotreitol-SDS. 
These samples and a sample of reduced 125I-C4 were applied to a 5-15% polyacrylamide gradient 
slab  gel and electrophoresis was performed. EACT4b2a  (NFc) was treated with:  C4-b.p +  C4b/ 
C3bINA  (track  1), C4-bp (track 2), C4b/C3bINA (track 3), and buffer (track 4). EAC14b2a  was 
treated with: C4-bp + C4b/C3bINA (track 5), C4-bp (track 6), C4b/C3bINA (track 7), and buffer 
(track 8). Track 9 depicts 125I-C4 used to prepare the cellular intermediates. 
autoradiograph  was  performed.  The  results  show  that  the EACT4b2a  (NFc)  were 
completely protected from the action of the control proteins. This was evidenced by 
the lack of radioactivity released into the supernate (Table I) and the intactness of the 
a' chain of C4b following treatment with C4b/C3bINA  alone or in addition to C4-bp 
(Fig. 5). In' contrast, the unstabilized EACT4b2a  released 50% of the radioactivity in 
the supernates  after treatment  with C4b/C3bINA  alone or with C4-bp.  SDS-PAGE 
analysis of these supernates revealed C4c  (a3, a4, fl, and y), whereas C4d  (a2) could 
be recognized as being attached  to the treated cells (Fig. 5). Incubation of EACT4b 
with  NFc failed to protect  C4b, which  indicates that  the effect of NFc is dependent 
upon the presence of the C2a, which must be bound to C4b  (C4b2a). 
The  functional activity of EAC14b2a  (NFc)  and EACT4b2a  after exposure to the 
control proteins, was investigated by measuring the capacity of the cellular interme- 
diates to cleave C3.  Although  the C4b/C3bINA  alone, or in  the presence of C4-bp, 8  MECHANISM  OF  ACTION  OF  THE  C4  NEPHRITIC  FACTOR 
abolished >50% of the C3 cleaving activity of the nonstabilized cell-bound convertase 
(Table II), the stabilized enzyme completely circumvented the effect of the control 
proteins.  Identical  C3  utilization  was  afforded  by EACT4b2a  (NFc),  which  was 
pretreated with buffer or with the control proteins. Moreover, the stabilized conver- 
tase, after incubation at 37°C, used the same number of C3 units without the addition 
of C2, whereas the nonstabilized convertase required, as was expected, additional C2. 
Discussion 
Regulation of the classical pathway G3 convertase is critical in determining whether 
the initial activation of the complement system leads to the formation of C3b, to the 
initiation  of the  amplification  step  mediated  by C3b,  and  to  the  assembly of the 
protein complex involved in the membrane attack. On erythrocyte-bound G4b2a, this 
regulation  is  exerted  through  at  least  three  different natural  mechanisms:  (a)  the 
intrinsic decay of the enzyme, which is the consequence of the temperature-dependent 
instability of the convertase (8), leading to the dissociation of C2a;  (b) an accelerated 
decay-dissociation of C2a from the C4b2a complex, which is mediated by the effect 
of the normal serum protein, C4-bp  (12); and  (c) the subsequent inactivation of the 
uncovered C4b by the serum enzyme C4b/C3bINA  (12). Proteolysis of the a' chain 
of C4b into C4c and C4d  (12)  by the C4b/C3bINA  prevents the formation of the 
classical pathway C3 convertase (12). 
Recently, a factor that is functionally characterized by its capacity to stabilize the 
classical pathway C3 convertase, was isolated from the plasma of a patient with acute 
postinfectious  glomerulonephritis  (18).  Similar  material  was  also  noted  in  some 
patients with SLE (19).  This factor was found to be associated with a serum protein 
that, according to its physicochemical and antigenic properties, could not be distin- 
guished  from  IgG  (18).  The  protein  binds  to EAC[4b2a,  but  not  to EAC14b  or 
EAC3bBb, and its biologic activity is associated with a portion of the molecule that 
behaves as the antigen-combining site of IgG. These findings are compatible with the 
concept that this IgG or "IgG-like" molecule is acting as an autoantibody (18), similar 
TABLE  II 
Effect of the Control Proteins C4-bp and C4b/C3blNA on C3 Consumption by 
EACf'4b2a and EAC]4b2a (NFc) 
Reaction mixture* 
Percent C3 used 
C2 +  C3  C3 added  added 
EACT4b2a, buffer  14  50 
EACT4b2a, C4-bp  4  46 
EACT4b2a, C4b/C3bINA  4  24 
EACT4b2a, C4-bp, C4b/C3bINA  2  20 
EACT4b2a (NFc), buffer  76  76 
EACT4b2a (NFc), C4-bp  75  76 
EACT4b2a (NFc), C3bINA  76  76 
EACT4b2a (NFc), C4-bp, C4b/C3bINA  74  76 
* Cellular  intermediates were  washed after 60  min  incubation with  control 
proteins or buffer. The cells were resuspended in buffer containing either C3 
alone, or C3 and C2. After 60 min of incubation, the cells were removed by 
centrifugation and the C3 in the supernate was measured hemolytically. GIGLI, SORVILLO, MECARELLI-HALBWACHS,  AND LEIBOWITCH 
to  the  C3Nef of the  alternative  pathway  (31).  The  stabilization  of the  classical 
pathway C3 convertase, recently ascribed to the C3Nef (32)  may in fact represent a 
protein identical to the one described here. 
Our investigation has permitted the elucidation of the mechanism(s) by which NFc 
regulates  the  classical  pathway  C3  convertase.  The  presence  of NFc  during  the 
formation of cell-bound C4b2a resulted in the generation of a larger number of C4b2a 
sites  (Fig.  1), as evidenced by a  greater hemolytic activity of the EAC~4b2a.  This 
augmented lysis was interpreted as being the consequence of enhanced cleavage of C3 
and C5 and the assembly of the proteins of the attack mechanism, which is probably 
a result of the stabilization of the convertase. The generation of an apparently larger 
number of C4b2a sites was the result of a  marked retardation in the intrinsic decay 
of C2a from the C4b2a complex, rather than an increased use of C2, leading to the 
formation of more C4b2a. Two lines of evidence support this view: (a) the generation 
of EAC~4b2a in the presence of NFc was associated with a lesser use of C2 in spite of 
the generation of a  large number of EAC4b2a  (Fig. 2); and  (b)  the prolongation of 
the half-life of the cell-bound enzyme from 7.5 min in the absence of NFc, to >5 h in 
its presence (Fig. 3). The effects of NFc were observed when it was added during the 
generation of the enzyme (Figs.  1 and 4), or during the decay process (Fig. 3). Thus, 
the increase in  the number of generated C4b2a  sites represents the formation of a 
stable convertase, in which the intrinsic decay of C2a is markedly retarded. Further, 
it  appears  that  NFc  can  also  generate  a  more stable  C5  convertase  (Fig.  2).  The 
capacity of the NFc used in these experiments to stabilize the C4b2a enzyme is greater 
than that isolated by Daha et al.  (13)  from patients with SLE, probably reflecting a 
greater affinity of this molecule for the C4b2a complex. 
Alone,  stabilization  of the  classical  pathway  convertase  in  the  presence  of the 
control proteins C4-bp and C4b/C3bINA could not account for the persistence of an 
active C4b2a complex in  serum  as was  seen in patient  R.  A.  M.  This observation 
prompted studies to examine whether NFc could interfere with the function of the 
control proteins.  30 times the amount of C4-bp  sufficient to reduce the half-life of 
C4b2a on sheep erythrocytes by 50% was ineffective in altering the decay of the NFc- 
stabilized convertase (Fig. 4). The resistance of C4b2a (NFc) to the accelerating effect 
of C4-bp on the decay dissociation of C2a was recently confirmed by the demonstra- 
tion of the limited ability of C4-bp  to dissociate a25I-C2 from the enzyme complex 
(13). Therefore, a second mechanism by which NFc induces enhanced C3 cleavage in 
serum can  be attributed  to the formation of a  classical pathway convertase that  is 
resistant to the regulatory action of C4-bp. 
The inability of C4-bp to accelerate the decay of C2a from C4b2a (NFc) suggested 
that the C4b in the complex was resistant to proteolytic cleavage by C4b/C3bINA. 
Indeed C4b,  in the NFc-stabilized convertase, was  found to maintain  its functional 
and structural integrity as shown by C3  use (Table II), and the preservation of the 
structure ofa' chain of C4b in the complex (Fig. 5). However, C2a must be complexed 
to C4b for NFc to exert its protective function, as demonstrated by the inability of 
this protein to prevent the proteolytic cleavage of C4b on the cellular intermediate in 
the absence of C2a. 
It should be noted that  the EACT4b2a  treated with C4b/C3bINA  alone was no 
longer capable of regenerating the convertase when additional C2 was added (Table 
II). There is an apparent disagreement of these data with those previously published 10  MECHANISM OF ACTION OF THE C4 NEPHRITIC FACTOR 
(12),  which demonstrated that EACT4b treated with C4b/C3bINA alone could bind 
and activate limited C2, whereas in the presence of C4-bp, no activation took place. 
This can be explained by the presence of uncleaved C4b sites  capable of binding C2 
in the absence of C4-bp but not in its presence. 
The resemblance of C3Nef (33-35) to NFc in the formation, decay, and regeneration 
of  the  classical  and  alternative  pathway  C3  convertases,  demonstrates  a  closer 
similarity between these two enzymes. Based on these similarities, it could be expected 
that  a  serum protein similar to properdin of the alternative  pathway (36-38)  could 
exist in normal human serum to stabilize the classical pathway enzyme. 
Summary 
Three mechanisms that regulate the formation and function of the classical pathway 
C3 convertase  (C4b2a)  have been  elucidated:  (a)  an  intrinsic  decay of the enzyme 
that  is temperature  dependent;  (b)  an extrinsic decay mediated by the effect of the 
serum  protein  C4b  binding  protein  (C4-bp);  and  (c)  inactivation  of C4b  by  the 
proteolytic action of C4b/C3b inactivator (C4b/C3blNA), which cleaves the a' chain 
of C4b  to yield C4d  (a2)  and C4c  (a3,  a4,/~,  and  3' chains).  A  fourth mechanism 
described here is based on the observation that the IgG fraction of the serum of certain 
patients with glomerulonephritis contains a protein termed C4 nephritic factor (NFc), 
which prevents the intrinsic decay of C4b2a. This protein, which prolongs the half- 
life of surface-bound C4b2a from 7.5 min to >5 h, increases the use of C3 and C5. It 
also inhibits the decay produced by C4-bp by preventing the dissociation of C2a from 
the C4b2a complex. Additionally, the C4b/C3bINA alone, or in the presence of C4- 
bp, fails to cleave the a' chain of C4b in the surface-bound stabilized C4b2a complex. 
This protective property of NFc requires the presence of C2a,  because C4b was not 
protected unless it was bound to C2a. Thus in the presence of NFc, the three natural 
controls of the function of the classical pathway convertase, intrinsic decay, extrinsic 
decay, and proteolytic cleavage, are bypassed. 
Received  forpublication  27January  198l and in revised  form  1 April 1981. 
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